Susanne Bard

2 months ago | today.ucsd.edu | Susanne Bard

Published Date February 07, 2025 Article Content This story is from the 2025 issue of Discoveries, a UC San Diego Health Sciences magazine. Imagine a patient rushed to the hospital during a heart attack. While performing CPR, the emergency medical team reaches for a ready-to-use epinephrine pen to restart the heart. But due to a shortage of the lifesaving pens, the provider has to grab a vial of epinephrine instead, remove the cap, swab it with alcohol and draw the medication out with a...

2 months ago | medicalxpress.com | Susanne Bard

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise. Now, researchers at University of California San Diego have discovered how healthy stem cells are transformed into cancer stem cells in the earliest stages of the disease. Oral cancer—also known as head and neck squamous cell carcinoma—affects the mouth, throat, nose, sinuses and voice box.

Dec 6, 2024 | medicalxpress.com | Susanne Bard

Researchers at University of California San Diego School of Medicine and their colleagues have developed the first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime. The study was published on December 5 in Nature Methods. The team quantified the gene expression of more than 58,000 individual hematopoietic (blood) stem cells at seven stages, from early fetal development to old age.

Nov 22, 2024 | medicalxpress.com | Susanne Bard

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected. The chemotherapy drug cisplatin, when administered alongside radiation therapy, is the gold standard for treating these malignancies.

Nov 18, 2024 | today.ucsd.edu | Susanne Bard

“We found that the probability of being alive and free of disease at two years was approximately 64% for cetuximab versus 51% for durvalumab, indicating no evidence of a benefit of durvalumab over cetuximab,” said Mell. “We had a lot of reasons to be optimistic about durvalumab, but it turned out to be potentially worse than the standard.”Monoclonal antibodies like cetuximab bind to proteins on the surface of cancer cells, halting their growth and proliferation.